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Therefore, noninvasive biomarkers that can predict plaque instability are needed. The LMPs, originating from
activated or apoptotic leukocytes, are the major microparticle (MP) subset in human carotid plaque extracts.Methods Forty-two patients with >70% carotid stenosis were enrolled. Using a new standardized high-sensitivity ﬂow
cytometry assay, LMPs were measured before thromboendarterectomy. The removed plaques were characterized as
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CD11bCD66bþ MPs (odds ratio: 24.4, 95% conﬁdence interval: 2.4 to 245, p < 0.01) independently predicted
plaque instability.Conclusions LMP constitute a promising biomarker associated with plaque vulnerability in patients with high-grade carotid
stenosis. These data provide clues for identifying asymptomatic subjects that are most at risk of neurologic
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1437(2,3). Identiﬁcation of biological and imaging markers of
atherosclerotic plaque vulnerability is important to pre-
dict which patients are most at risk for neurologic
events. Membrane microparticles (MP) released by ap-
optotic or activated cells (such as endothelial cells, leuko-
cytes, and platelets) have been reported to be sensitive
markers of atherothrombotic disease progression and
potential effectors of vascular dysfunction (4–6). Inte-
restingly, increased leukocyte-derived microparticles (LMP)
See page 1442
levels are present in the plasma of patients with cardiovas-
cular risk factors (7) or subclinical atherosclerosis as assessed
by ultrasonography (8). The LMPs were found to be the
major MP subpopulation in extracts from human plaques
after carotid endarterectomy (9). Given the critical involve-
ment of leukocyte activation in plaque formation and
destabilization (10), our objective was to test whether plas-
matic level of LMP in patients with high-grade carotid
stenosis undergoing systematic surgery could be useful to
identify patients with unstable plaques.
Methods
Patients. Forty-two patients with high-grade carotid ste-
nosis who were undergoing carotid endarterectomy in the
vascular surgery department of Timone Hospital were
enrolled from June 2009 to June 2010 after informed consent
was obtained and procedures approved by the local human
ethics committee. During the inclusion period, 38 patients
were not included because of unavailable biological or
histological samples or patient’s rejection or patients with
patent clinical infection signs, chronic inﬂammatory diseases,
or cancer. The NASCET (North American Symptomatic
Carotid Endarterectomy Trial) clinical criteria (1) were used
to classify patients as neurologically symptomatic or asymp-
tomatic. High-grade carotid stenosis was deﬁned on
computed tomography as a 70% reduction in diameter
using the NASCET trial technique (1). For the LMP and
high-sensitivity C-reactive protein analyses, blood sampling
was performed just before surgery after an overnight fast.
Surgically removed carotid plaques were collected for histo-
pathological analysis. A group of 20 age-matched healthy
volunteers with no cardiovascular risk factors and no medi-
cations were recruited as controls.
Leukocyte-derivedmicroparticlemeasurement using high-
sensitivity ﬂow cytometry. Venous blood was collected into
0.129 mol/l tri-sodium citrate Vacutainer tubes (BD Diag-
nostics, Franklin Lakes, New Jersey). Platelet-free plasma
was prepared within 4 h using 2 serial centrifugations (15
min at 1,500g, 2 min at 13,000g) and stored at 80C until
use. For the MP labeling, 30 ml freshly thawed platelet-free
plasma was incubated for 30 min at room temperature
with 10 ml conjugated monoclonal antibodies (CD11b-
FITC [clone Bear1’] and CD66b-FITC [clone UCHT1]or CD15-FITC [clone 80H5])
or isotype and concentration-
matched control antibodies from
Beckman Coulter (Marseille,
France). The platelet-free plasma
was then diluted in phosphate-
buffered saline without calcium
and magnesium. Then, 30 ml
Cyto-Count Fluorospheres (Dako,
Trappes, France) was added to
determine the absolute MP numbers. The LMP determi-
nation was performed on a high-sensitivity ﬂow cytometer
(Gallios Instrument, Beckman Coulter). Protocol standard-
ization was based on a blend of ﬂuorescent size-calibrated
beads (0.1, 0.3, 0.5, and 0.9 mm [Megamix-Plus prototype,
Biocytex, Marseille, France]) (11). To obtain better sensi-
tivity in the low size range, the Gallios ﬂow cytometer was set
up in the “W2” mode. The lower and upper limits of the MP
gate were deﬁned using 0.3-mm and 0.9-mm beads, respec-
tively (12). To evidence the speciﬁc advantage of high-
sensitivity ﬂow cytometry, LMP determination was also
performed on a previous-generation instrument FC500
(Beckman Coulter) with a lower limit of MP gate at
0.5 mm beads-equivalent. The LMP were deﬁned as the
CD11bCD66b or CD15 positive events included in the MP
region, and the results were expressed as the number of MP/
ml of plasma.
Histological assessment of the carotid plaques. The
samples were ﬁxed for 24 h in 4% neutral buffered formalin,
dehydrated in graded alcohols, cleared in xylene, and embedded
in parafﬁn. Hematoxylin-and-eosin staining were performed
on serial sections (5 mm) of each sample, and morphological
characteristics of the plaques were established according to the
classiﬁcation deﬁned by the American Heart Association
(AHA) (13). The stable lesions are AHA type V: ﬁbrous
connective tissue together with extracellular lipids and lami-
nated acellular collagen without endothelial disruption (Va) or
only ﬁbrous conjunctive tissue (Vb). The unstable lesions are
type VI: ulceration of the endothelial surface (VIa) or recent
intraplaque hemorrhage (VIb) or intraplaque thrombosis (VIc).
Six sections were analyzed from each patient.
Statistical analysis. First, the patient characteristics were
compared according to the plaque morphology. The results
were expressed as median (25th percentile to 75th per-
centile). Bivariate comparisons were conducted using the
Mann-Whitney U test for continuous characteristics and
the chi-square or Fisher exact tests for categorical charac-
teristics. Wilcoxon matched pairs test was used to compare
LMP levels from the 2 ﬂow cytometry strategies. Spear-
man’s rank correlation coefﬁcients were calculated to
determine the strength of the association between the
continuous characteristics. A receiver-operating character-
istic curve analysis was then conducted to identify the
threshold level of LMPs that was capable of predicting an
unstable plaque with the shortest distance from the upper
left corner of the receiver-operating characteristic curve
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1438(minimizing [(1-sensitivity)2 þ (1-speciﬁcity)2]). Positive
predictive value (PPV) and negative predictive value (NPV)
were analyzed.
Amultivariate analysis was carried out by creating a forward
stepwise logistic regressionmodel to estimate the probability of
an unstable plaque. First,we veriﬁed that neurologic events and
CD11b66bþ MP level were independently associated with
the presence of unstable plaque. Then, age, sex, treatments
(antiplatelets, statins, angiotensin-converting enzyme inhibi-
tors), and factors associated with the outcome at the p < 0.20
level in the bivariate analyses (LMP, hypertension, diabetes
mellitus, hypercholesterolemia, smoker, stenosis degree, low-
density lipoprotein cholesterol, high-sensitivity C-reactive
protein) were considered eligible to enter into the logistic
regressionmodel.This forward approachwas based on the log-
likelihood ratio test (entry threshold: p < 0.05). Low-density
lipoprotein cholesterol level was secondarily removed from
the candidate variables because it was far from statistical
signiﬁcance and had 1 missing datum. The logistic regression
model was applied to the whole population and to the pop-
ulation of asymptomatic patients. The only difference was that
antiplateletswere not considered in the second analysis because
all the asymptomatic patients had such a treatment. Statistical
analyses were performed using SPSS version 17.0. (SPSS,
Chicago, Illinois). Any p value <0.05 was considered statis-
tically signiﬁcant.Results
Participant characteristics. In the whole population,
patients with stable and unstable plaques displayed similar
characteristics except for neurologic symptoms, signiﬁcantlyTable 1
Clinical, Therapeutic, and Biological Characteristics of All P
According to Plaque Morphology
Whole Population
Stable Plaque
(n ¼ 14)
Unstable Plaque
(n ¼ 28)
Age, yrs 77.0 (62–80) 72.5 (66–76)
Male 10 (71.4) 22 (78.6)
Body mass index, kg/m2 25.4 (24.2–28.1) 25.2 (24.0–27.0)
Hypertension 12 (85.7) 17 (60.7)
Diabetes mellitus 5 (35.7) 4 (14.3)
Hypercholesterolemia 13 (92.9) 16 (56.5)
Smoker 4 (28.6) 9 (57.1)
Antiplatelets 14 (100) 26 (92.9)
Statins 9 (64.3) 15 (53.6)
ACE inhibitors 7 (50.0) 9 (32.1)
Neurologic event 1 (7.1) 18 (64.3)
LDL cholesterol, g/l 0.93 (0.8–1.0) 1.2 (0.9–1.2)
hs-CRP, mg/l 3.0 (1.6–4.8) 7.0 (2.0–21.3)
Leukocyte count 8.0 (6.7–9.9) 7.9 (6.6–9.7)
CD11b66b count 16 (0–234) 240 (147–394)
CD15 count 55 (36–157) 147 (60–635)
Values are median (25th percentile to 75th percentile) or n (%). Bold indicate p < 0.02.
ACE ¼ angiotensin-converting enzyme; hs-CRP ¼ high-sensitivity C-reactive protein; LDL ¼ low-densityhigher in the patients with unstable plaque, and hypercho-
lesterolemia, signiﬁcantly higher in the patients with stable
plaque. Overall, 23 patients were asymptomatic. No signiﬁ-
cant differences were observed between the asymptomatic
patients classiﬁed according to plaque morphology (Table 1).
Age of healthy controls and of the whole population of
patients was similar as attempted (healthy controls: 67 [66 to
69] years, and entire population of patients: 73 [63 to 78]
years; p ¼ 0.32).
Circulating leukocyte-derived microparticles are increased
in patients with unstable plaque. In the whole population
of patients with carotid stenosis, the median plasmatic LMP
levels, as assessed by CD11b66bþ or CD15þ labeling and
high-sensitivity ﬂow cytometry analysis, were signiﬁcantly
higher compared to those of healthy controls (181 [70 to 324]
MP/ml and 90 [51 to 233] MP/ml vs. 2 [0 to 5] MP/ml and 2
[0 to 16] MP/ml, respectively; p < 0.05). In the whole pop-
ulation of patients, the levels of both types of LMPs were
signiﬁcantly correlated (rho ¼ 0.57; p < 0.001; n ¼ 42).
The level of CD11b66bþ LMP was signiﬁcantly higher in the
patients with unstable plaque compared to patients with stable
plaque (240 [147 to 394] MP/ml vs. 16 [0 to 234] MP/ml; p <
0.001) (Fig. 1). Similarly, a signiﬁcant increase in the level of
CD15þ LMP was observed in the patients with unstable
plaque compared to patients with stable plaque (147 [60 to
635] MP/ml vs. 55 [36 to 157] MP/ml; p < 0.01) (Fig. 1).
Interestingly, among the asymptomatic patients, the
median levels of the LMP subsets remained signiﬁcantly
higher in patients with unstable plaque compared to patients
with stable plaque (CD11b66bþ MP/ml 199 [153 to 410]
vs. 20 [0 to 251], p < 0.05; CD15þ MP/ml 78 [56 to 258]
vs. 55 [34 to 102], p < 0.05) (Fig. 2).atients and Asymptomatic Patients
Asymptomatic Patients
p Value
Stable Plaque
(n ¼ 13)
Unstable Plaque
(n ¼ 10) p Value
0.42 78.0 (62–80) 73.0 (70–78) 0.93
0.71 9 (69.2) 8 (80.0) 0.66
0.94 25.6 (24.4–28.4) 25.9 (24.8–29.4) 0.74
0.16 11 (84.6) 6 (60.0) 0.34
0.13 5 (38.5) 3 (30.0) 0.99
0.03 12 (92.3) 7 (70.0) 0.28
0.99 4 (30.8) 2 (20.0) 0.66
0.55 13 (100) 10 (100.0) d
0.51 9 (69.2) 7 (70.0) 0.99
0.32 6 (46.1) 6 (60.0) 0.68
0.001 0 0 d
0.15 0.92 (0.7–1.0) 0.90 (0.9–1.0) 0.61
0.16 3.0 (1.6–4.3) 2.0 (1.2–4.0) 0.59
0.58 7.8 (6.6–9.2) 7.4 (5.9–8.2) 0.56
0.001 20 (0–251) 199 (153–410) 0.02
0.009 55 (34–102) 78 (56–258) 0.04
lipoprotein.
Figure 1
Plasmatic levels of CD11b66bþ MP and CD15þ MP
in Patients With High Grade Carotid Stenosis
Plasmatic levels of CD11b66bþ microparticles (MP) and CD15þ MP as assessed
by high-sensitivity ﬂow cytometry were signiﬁcantly increased in patients with
unstable plaques compared to patients with stable plaques (**p < 0.01, ***p <
0.001; n ¼ 42). The thick black line inside the boxes indicates the median.
The top and bottom of the box indicate 25th percentile and 75th percentile.
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1439By contrast, no signiﬁcant difference between patients
with unstable plaque and patients with stable plaque could
be evidenced when CD11b66bþ LMP was quantiﬁed
by previous-generation ﬂow cytometry analysis (whole
population 18 [11 to 32] MP/ml vs. 13 [0 to 27] MP/ml, andFigure 2
Plasmatic levels of CD11b66bþMPs and CD15þMPs
in Asymptomatic Patients With High Grade Carotid
Stenosis
Plasmatic levels of CD11b66bþ microparticles (MP) and CD15þ MP as assessed
by high-sensitivity ﬂow cytometry were signiﬁcantly increased in asymptomatic
patients with unstable plaques compared to patients with stable plaques
(*p < 0.05, n ¼ 23). The thick black line inside the boxes indicates the median.
The top and bottom of the box indicate 25th percentile and 75th percentile.asymptomatic patients 18 [15 to 36] MP/ml vs. 13 [0 to 26]
MP/ml).
Circulating leukocyte-derived microparticles independently
predict plaque instability. A receiver-operating characteristic
analysis indicated that the cutoff point for LMP that best
predicted the presence of unstable plaque was 120 MP/ml for
CD11b66bþ MPs with an 82% sensitivity, a 71% speciﬁcity,
an 85% PPV, and a 67% NPV (Table 2). For CD15þ LMP,
the cut-off was 58 MP/ml with a 79% sensitivity, a 71%
speciﬁcity, a 85% PPV, and a 62% NPV (Fig. 3A).
In the asymptomatic patients, the cutoff points for LMP
that best predicted the presence of unstable plaque were
found to be the same (120 for CD11b66bþ MPs with
a 90% sensitivity, a 69% speciﬁcity, a 69% PPV, and a 90%
NPV; and 58 for CD15þ MPs with an 70% sensitivity,
a 77% speciﬁcity, a 70% PPV, and a 77% NPV) (Fig. 3B).
After logistic regression, both the neurologic symptoms
and the level of CD11b66bþ MP were identiﬁed as inde-
pendent predictors of unstable plaques (neurologic symp-
toms odds ratio [OR]: 48.7, 95% conﬁdence interval [CI]:
3.0 to 788, p < 0.01; CD11b66bþ MP >120 OR: 24.4,
95% CI: 2.4 to 245, p < 0.01). In the asymptomatic
patients, only the level of CD11b66bþ MP was associated
with unstable plaques (level >120 OR: 20.3, 95% CI: 1.9 to
219, p < 0.01).
Discussion
The annual risk of ischemic stroke secondary to a 60%
asymptomatic carotid stenosis has been reported to be 2% to
3% in randomized trials of endarterectomy versus best
medical therapy (3). However, thanks to medical treatment
improvement, this risk has been reduced to 0.4% (2), and
surgery is likely to be performed for patients with a high
neurologic risk. Thus, identiﬁcation of markers of plaque
instability is interesting to make this selection possible.
However, none of the circulating markers previously tested
for their ability to predict vulnerable carotid plaques allowed
differentiation of stable and unstable plaques in asymptom-
atic patients (14). To our knowledge, this is the ﬁrst study to
demonstrate that high plasmatic level of LMP is associated
with unstable plaque in asymptomatic patients with high-
grade carotid stenosis. Thus, LMP behave as a new poten-
tial biomarker that could be used to identify asymptomatic
subjects who are most at risk of neurologic events.
In a previous study (9), MP subsets were measured in
plaque extracts after carotid endarterectomy in asymptomatic
and symptomatic patients. Although a high proportion of
plaque MP was found to originate from leukocytes, circu-
lating level of LMP failed to differentiate the 2 groups of
patients. Here, we used a new standardized high-sensitivity
ﬂow cytometry method to measure circulating LMP levels.
This method, providing improved resolution and decreased
background noise, allows the measurement of previously
undetectable small MP subpopulation in a standardized
manner (12). Consistently, LMP levels measured in patients
Table 2
Estimates (95% Conﬁdence Intervals) of Association Between Circulating Leukocyte-Derived Microparticles and
Plaque Instability
Patients Microparticles Sensitivity Speciﬁcity Positive Predictive Value Negative Predictive Value
Whole population (n ¼ 42)
CD11b66bþ MP >120 0.82 (0.63–0.94) 0.71 (0.42–0.92) 0.85 (0.66–0.96) 0.67 (0.38–0.88)
CD15þ LMP >58 0.79 (0.59–0.92) 0.71 (0.42–0.92) 0.85 (0.65–0.96) 0.62 (0.35–0.85)
Asymptomatic population (n ¼ 23)
CD11b66bþ MP >120 0.90 (0.55–1.00) 0.69 (0.39–0.91) 0.69 (0.39–0.91) 0.90 (0.55–1.00)
CD15þ LMP >58 0.70 (0.35–0.93) 0.77 (0.46–0.95) 0.70 (0.35–0.93) 0.77 (0.46–0.95)
LMP ¼ leukocyte-derived microparticles; MP ¼ microparticles.
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1440with carotid stenosis were found to be higher than those
determined using previous-generation ﬂow cytometry that
do not give reliable access to small-size events. In addition,
we demonstrated that including these small-size MP frac-
tions identiﬁes an excessive leukocyte vesiculation occurring
in patients with histologically deﬁned unstable carotid pla-
que compared to patients with stable plaque, whereas the
previous-generation method failed to do so. Elevation of
LMP subsets remained signiﬁcant when only asymptomatic
patients were considered.
After adjustment for neurologic symptoms, LMP were
independently associated with plaque instability. Importantly,
medical therapy with angiotensin-converting enzyme inhibi-
tors or statins is presumably able to stabilize atherosclerotic
plaques andmay inﬂuence circulatingMPlevels (15).However,
we did not observe any difference in LMP levels between
patients taking or not taking these drugs (data not shown). In
addition, these treatments were included in the logic regression
model attesting that the link between LMP and plaque
vulnerability was independent of medical therapy. These data
indicate that CD11b66bþ LMP levels are a promising markerFigure 3 ROC Curve Analysis
Receiver-operating characteristic (ROC) analysis was used to determine the threshold of le
sensitivity and speciﬁcity. (A) Whole population, area under the curve (AUC) CD11b66bþ
0.91). (B) Asymptomatic patients, AUC CD11b66bþ MP (solid line) 0.80 (0.62 to 0.99),
derived MP that best predicted the presence of unstable plaques was 120 for CD11b66bþ
the curve ¼ 0.5).of plaque instability. By contrast, an independent association
betweenLMP expressingCD15 and plaquemorphology could
not be evidenced. This result suggests that, depending on the
marker used, LMP subsets may have various pathological roles
and clinical signiﬁcances, and is consistent with the fact
that these markers do not identify strictly similar subpopula-
tions of leukocytes. In contrast to CD15, present mainly in
granulocytes, CD11b is also expressed by leukocyte subpopu-
lations that make signiﬁcant contributions to atherosclerosis
progression, such as monocytes, CD8þ T lymphocytes and
NK cells (16). In addition, the high expression levels of CD11b
and CD66b on parental leukocytes contribute to optimize the
sensitivity for MP detection.
The pathophysiological mechanisms underlying the
elevation of circulating LMP in patients with unstable carotid
plaque remain to be elucidated. One hypothesis is that LMP
are generated within the blood compartment or at the vessel
wall interface as a result of inﬂammatory processes, which
drives plaque instability. In our study, a role for systemic
inﬂammation is unlikely because no signiﬁcant elevation of
high-sensitivity C-reactive protein was noted in patients withukocyte-derived microparticles (MP) that predicts an unstable plaque with the highest
MP (solid line) 0.81 (0.65 to 0.96), and AUC CD15þ MP (dotted line) 0.75 (0.60 to
and AUC CD15 MP (dotted line) 0.75 (0.55 to 0.96). The cutoff point for leukocyte-
MP and 58 for CD15þ MP. The dashed line indicates the reference line (area under
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1441unstable plaque. In addition, the levels of phosphatidylserine-
positive MP and endothelial-derived MP, classically in-
creased during systemic inﬂammation, were similar in the 2
groups of patients (data not shown). Another hypothesis is
that LMP originated from plaque rupture because high
amounts of MP resulting from apoptotic leukocytes have
been reported in vulnerable plaques (9). These MP could be
a major determinant of plaque instability because they
promote thrombogenicity (9), stimulate endothelial pro-
liferation and intraplaque neovascularization through a
CD40-to-CD40L interaction (17), and promote leukocyte
recruitment (18) by the transfer of intercellular adhesion
molecule-1 to endothelial cells.
Study limitations. The potential limitations of this study
include the limited number of subjects and the absence of
patient follow-up regarding neurologic events. Particularly,
the limited number of subjects limits our inferences regarding
the lack for confounding of the several cardiovascular risk
factors measured, because of potential over-ﬁtting of multiple
logistic regression models. In the same way, the single dataset
used to establish MP thresholds and to assess performance
may have over-estimated sensitivity, speciﬁcity, and positive
and negative predictive values. Future large-scale prospective
studies are needed to establish whether LMP levels display
prognostic value with respect to the occurrence of neurologic
events, and whether LMP levels could be used as a noninva-
sive biomarker with decision-making value in an asymp-
tomatic population of patients who are considered for
preventive carotid endarterectomy. One prerequisite is also to
extend data on the clinical stability of these markers.
Conclusions
Among the asymptomatic patients with high-grade carotid
stenosis, increased circulating LMP level may be useful in
identifying a subgroup of patients with histologically deﬁned
plaque instability. The LMP may constitute a promising
biomarker for the diagnosis of carotid plaque vulnerability
and provide encouraging clues for the identiﬁcation of
asymptomatic subjects at high neurologic risk who would
beneﬁt the most from carotid surgery.Acknowledgments
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